Novo Nordisk (CPSE:NOVO B) Taps DJ Khaled As Oral Weight Loss Race Heats Up

What happened: Novo Nordisk (CPSE:NOVO B) partnered with DJ Khaled to promote his Wegovy weight loss journey to a wider US audience, as Eli Lilly received the first Chinese regulatory approval for an oral GLP-1 weight loss pill. Key numbers: Novo Nordisk is described as a DKK1.2 trillion pharmaceuticals heavyweight, with a DKK298 fair value cited; oral Why it matters: The marketing push aims to frame obesity as a chronic condition treated long term, while Eli Lilly's early oral GLP-1 approval in China speaks to the risk that rivals and pricing pressure could limit GLP-1 driven earnings. Market: -0.7% today ($1,427.28), +32.6% YTD, 0.9x vol — as of 12:45 UTC

Novo Nordisk (CPSE:NOVO B) partnered with DJ Khaled to promote his Wegovy weight loss journey to a wider US audience, as Eli Lilly received the first Chinese regulatory approval for an oral GLP-1 weight loss pill.

The marketing push aims to frame obesity as a chronic condition treated long term, while Eli Lilly's early oral GLP-1 approval in China speaks to the risk that rivals and pricing pressure could limit GLP-1 driven earnings. Market: -0.7% today ($1,427.28), +32.6% YTD, 0.9x vol — as of 12:45 UTC